Arcturus Therapeutics Third Quarter 2026 Earnings Call - ARCTURUS THERAPEUTICS HOLDINGS INC

Explicit Guidance:

• ARCT-2601 (OTC Deficiency): Initiate Phase 2 dosing in Q1 2027; report top-line data in the second half of 2027.
• ARCT-032 (Cystic Fibrosis): Complete enrollment by year-end 2026 (end of calendar year); present full cohort data in Q2 2027. Top-line data expected prior to the full data presentation.
• ARCT-2601 PKU Program: Submit Investigational New Drug (IND) application in the second half of 2027.
• COStAVE (Vaccine): Target commercial objectives in 2027 (EU and UK); U.S. commercialization via partner.
• Financials: Maintain cash runway of over two years through year-end 2028 ($184.8M cash on hand as of Q3 2026).

Business-Segment Outlook:

• Liver Therapeutics: Entering a new phase with ARCT-2601, the first mRNA therapeutic using Lunar 2.0 delivery technology (demonstrating a 38-fold potency improvement vs. original Lunar in NHP models). Aiming to broaden disease addressability beyond OTC to Phenylketonuria (PKU) and Gout.
• Respiratory Franchise (CF): Enrolling ~20 Class 1 CF subjects in Cohort 4 (10mg dose, inhaled, 12 weeks). Aiming for a go/no-go decision based on top-line data available before the Q2 2027 presentation to potentially advance to Phase 3.
• Vaccine Enterprise: COStAVE (self-amplifying mRNA) currently commercialized in Japan for the 2026-2027 season; regulatory rights transferred to Arcturus in EU and UK to enable 2027 commercial execution. Phase 1 pandemic influenza vaccine data shows single-dose potential.
• Pipeline Expansion: Integrating MyNeo's AI-driven antigen design capabilities to accelerate oncology and neoantigen vaccine development.

Market and Competitive Outlook:

• Competitive Landscape (CF): Arcturus contrasts with competitor programs (e.g., Vertex) that halted due to safety/tolerability requiring systemic steroids; Arcturus protocol uses only standard bronchodilators for the first two weeks, allowing home administration, avoiding the clinic-based administration failure points of competitors.
• Regulatory Strategy: Leveraging the REACH Study (natural history database from CF Foundation) to potentially enable smaller Phase 3 trials using external controls, minimizing placebo arms.
• Supply Chain/Collaboration: Thermo Fisher Scientific to provide significant contributions if ARCT-032 advances to Phase 3; Arcturus retains control over the go/no-go decision.

Macro / Industry Outlook:

• Regulatory: Favorable feedback received from FDA Type C meetings regarding ARCT-2601 and Lunar 2.0 pathway.
• Pandemic Preparedness: Management anticipates continued public funding opportunities (e.g., BARDA contracts) for self-amplifying mRNA pandemic vaccines (bird flu, influenza) given the single-dose advantage.
• Oncology: Market interest in neoantigens and mRNA vaccines is described as a "hotter topic," positioning Arcturus' acquired MyNeo capabilities for future strategic opportunities.

Strategic Initiatives:

• Technology Launch: Deployment of Lunar 2.0 platform to enable lower frequency dosing and address new genetic indications (PKU, Gout).
• M&A Integration: Completed acquisition of MyNeo to add AI-driven capabilities in antigen design and mRNA optimization; integration expected to accelerate pipeline development.
• Commercial Transfer: Completed transfer of COStAVE marketing authorization rights from CSL Seqirus to Arcturus in EU and UK.
• Capex/Opex Discipline: Reduced R&D expenses year-to-date driven by lower headcount and reduced activities on lower-priority programs (Lunar COVID, BARDA); continued focus on high-priority therapeutic programs.

Risks and Headwinds to Outlook:

• Clinical Translation: The 38-fold potency improvement observed in non-human primates for ARCT-2601 has not yet been confirmed in humans; success depends on this translation.
• Timeline Uncertainty: Initiating a Phase 3 CF study by late 2027 is described as "speculative" and a "push," contingent on Q2 2027 data and subsequent agency engagement.
• Data Presentation Risk: Top-line data for CF (Q2 2027) and ARCT-2601 (H2 2027) are subject to the success of the 12-week treatment period and safety monitoring.
• Regulatory Endpoints: FDA agreement on primary/secondary endpoints for Phase 3 OTC studies (focusing on ammonia/glutamine stabilization) is anticipated but requires confirmation in future data sets.
• Funding: While cash runway is strong, continued execution relies on maintaining disciplined capital allocation.

Management Tone on the Future:

• Confidence: High confidence in Lunar 2.0's 38-fold potency jump and its translation to patients; confident that 12 weeks is sufficient to capture clinical signal in CF.
• Strategic Focus: Explicitly stating a focus on "mRNA therapeutics" and "liver therapeutics" as the core, with oncology as an enabler via partnerships rather than a primary standalone venture.
• Tone: Optimistic regarding the "new, exciting phase" of the liver franchise and the "breadth" of the platform, while maintaining a disciplined, risk-mitigated approach to capital allocation.

Miscellaneous:

• Patient Selection (ARCT-2601): Plan to enroll up to 6 subjects for the initial Phase 2 cohort, prioritizing patients with elevated baseline ammonia/glutamine levels to maximize observable deltas and clinical signal.
• Study Design (CF): Cohort 4 is an open-label study with restricted access to real-time efficacy data (limited to medical team/safety monitoring) to prevent bias; safety data shows no severe adverse events to date among patients completing 12 weeks.
• FDA Engagement: Plan to present combined ARCT-2601 and ARCT-810 data at an End-of-Phase 2 meeting to design the Phase 3 program.